third-line therapy

third-line therapy

Any alternative to conventional–surgery, chemotherapy or RT for malignancy. Cf Unproven forms of cancer therapy.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Stevens's third-line therapy is intravenous abatacept at 10 mg / kg monthly along with intravenous methylprednisolone at 500 mg/ week.
If this combination doesn't provide satisfactory improvement after adequate dosing for sufficient duration, only then is it time to turn to an atypical antipsychotic agent as a higher-risk/higher-reward third-line therapy, added Dr.
Jung, "Current status of second-line and third-line therapy for Helicobacter pylori eradication in Korea," The Korean Journal of Helicobacter and Upper Gastrointestinal Research, vol.
In this case, we changed dasatinib to bosutinib as a third-line therapy because there was no report of bosutinib-induced PAH at the time of the medication switch.
We studied patients with type 2 diabetes mellitus newly dispensed with either NPH insulin or a DPP-4 inhibitor as third-line therapy between January 2011 and December 2014.
Lithium traditionally has been prescribed as third-line therapy in refractory patients for severe unipolar depression.
Treatment of idiopathic overactive bladder often requires third-line therapy, which includes onabotulinumtoxinA, posterior tibial nerve stimulation, and sacral neuromodulation.
Data suggests that median survival on relapse is less than two years from the start of second-line therapy and around one year from the initiation of third-line therapy.
After treated with vinorelbine and/or gemcitabine as second- or third-line therapy, 46% of patients had stable disease.[sup][15] Combination chemotherapy using gemcitabine with vinorelbine was shown to achieve 82% disease control (stable disease + partial response + complete response) in 17 Japanese MPM patients pretreated with platinum plus pemetrexed chemotherapy.[sup][16]
To our knowledge, this is the first multicentre survey to investigate the effectiveness of targeted therapies related to bone metastases in patients who received third-line therapy for mRCC.
It is a randomised phase II trial of cabozantinib and erlotinib, alone or in combination, as second- or third-line therapy in patients with metastatic EGFR wild-type non-small cell lung cancer.

Full browser ?